Healthcare Industry News: Covered Stent
News Release - September 30, 2008
ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
OR AKIVA, Israel, September 30 (HSMN NewsFeed) -- ITGI Medical, Ltd. (TASE: ITGI) a company engaged with research, development, manufacturing and marketing of heterologous tissue Covered Stents, announced that its second heterologous tissue Covered Stent - AneuGraft® received CE Mark approval.AneuGraft® is a stent 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. It is intended for situations in tortuous vessels.
"AneuGraft® Pericardium Covered Stent is especially suitable for patients with tortuous vessels where other Covered Stents may not be adequate for use due to limitations resulting from tortuous anatomy," says Efri Argaman ITGI Medical CEO.
The CE Mark approval for AneuGraft® will enable ITGI Medical to provide a wide range of coronary interventional solutions for all those situations that need to set a barrier between the vessel wall and its lumen, despite the anatomical limitations. The AneuGraft® is mounted on a delivery system specially designed to improve the stent navigability in tortuous vessels.
About AneuGraft®
AneuGraft ® is a unique stent, second in a series of heterologous tissue Covered Stents, designed to set a barrier between the blood vessel wall and its lumen. AneuGraft ® PCS is indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations in tortuous vessels.
About ITGI Medical
ITGI medical is engaged with research and development, manufacturing and marketing of heterologous tissue Covered Stents. Over and Under® is the first among series of heterologous Covered Stents designed to treat coronary lesions and aneurysms. The world stent market has a value estimation of 6.4 Billion USD, of which 37% are generated in the USA.
Source: ITGI Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
